Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Trigone Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trigone Pharma to Present Preclinical Data for TRG-100 in Interstitial Cystitis \/ Bladder Pain Syndrome at the AUA Conference","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Trigone Pharma"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Imbrium Therapeutics","pharmaFlowCategory":"D","amount":"$59.5 million","upfrontCash":"Undisclosed","newsHeadline":"PureTech Announces That Imbrium Therapeutics Has Exercised License Option to LYT-503\/IMB-150 for Interstitial Cystitis\/Bladder Pain Syndrome","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"PureTech Health"},{"orgOrder":0,"company":"Versameb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Versameb to Present Novel Data on Its Lead Asset, VMB-100 at 9th International mRNA Health Conference","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Versameb"},{"orgOrder":0,"company":"Touchlight","sponsor":"Versameb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight and Versameb Announce GMP Manufacturing Supply Agreement","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Touchlight"},{"orgOrder":0,"company":"Valensa International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valensa\u2019s Chief Science Officer Presents New Research on Efficacy of a Lipidosterolic Extract of Saw Palmetto","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Valensa International"},{"orgOrder":0,"company":"Versameb","sponsor":"Touchlight","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Touchlight\u2019s Enzymatic Doggybone DNA used in the Manufacture of Versameb\u2019s VMB-100 for First-in-human Clinical Study","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Versameb"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), is being developed to treat chronic stress urinary incontinence (SUI).

            Lead Product(s): VMB-100

            Therapeutic Area: Urology Product Name: VMB-100

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Touchlight

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of novel mRNA-based therapeutics, including VMB-100, addressing unmet needs in urology and oncology.

            Lead Product(s): VMB-100

            Therapeutic Area: Urology Product Name: VMB-100

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Versameb

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Strum’s findings validate the effectiveness of an LSESr like Valensa’s USPlus® Pure Lipidosterolic Extract of Serenoa repens (LSESr), commonly known as saw palmetto, for improved quality of life in men with lower urinary tract symptoms (LUTS).

            Lead Product(s): Serenoa Repens Extract

            Therapeutic Area: Urology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter. VMB-100 shows therapeutic potential in Stress Urinary Incontinence.

            Lead Product(s): VMB-100

            Therapeutic Area: Urology Product Name: VMB-100

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 04, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Imbrium is responsible for all future development activities and funding for LYT-503/IMB-150, for which an IND filing is planned for early 2022.

            Lead Product(s): IMB-150

            Therapeutic Area: Urology Product Name: LYT-503

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Imbrium Therapeutics

            Deal Size: $59.5 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 11, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The in-vitro and animal data suggest that TRG-100 can safely be used for possible intravesical sustained release of Lidocaine and Oxybutynin in the treatment of BPS/IC.

            Lead Product(s): Oxybutynin,Lidocaine

            Therapeutic Area: Urology Product Name: TRG-100

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 22, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY